Compare Amphastar Pharmaceuticals Inc (AMPH) vs Xcel Energy Inc (XEL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

XEL trades at $80.06, up 1.32% today, with a bearish technical signal but strong analyst consensus. Recent earnings showed a Q1 2026 beat but two prior misses. The company maintains solid fundamentals with $14.67B revenue, 14.14% net margin, and a $60B capital plan driving growth. Dividend yield is 2.87% with a recent $0.59 payout declared.

Outlook is positive with Wall Street's $91.88 price target suggesting 15% upside, supported by data center demand and infrastructure investments. Risks include regulatory pushback on rate hikes and high debt levels. The stock presents a steady utility play with growth catalysts but requires monitoring of earnings consistency and capex execution.